BioArctic

About Us

BioArctic AB is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. BioArctic focuses on innovative treatments in areas with high unmet medical needs. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

BioArctic announces changes in the Management Team effective September 1, 2018

Wed, Jun 27, 2018 07:00 CET

Stockholm, Sweden, June 27, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that professor Lars Lannfelt resumes his employment in the company as of September 1, 2018. Professor Lannfelt is one of the two founders, member of the Board, the largest owner and has today a consultancy role in the company. In the future he will work full-time as scientific expert with new discovery opportunities and continue to be the company's contact person in the strategically important collaborations with research groups at the universities. Associate Professor Pär Gellerfors founded

There are no items matching the current filter

There are no more items matching the current filter

Back to top

About Us

BioArctic announces changes in the Management Team effective September 1, 2018

Subscribe

Media

Share

About Us

BioArctic announces changes in the Management Team effective September 1, 2018

Subscribe

Media